Biotech
Commented by Stefan Feulner on June 4th, 2024 | 07:00 CEST
Canopy Growth, Vidac Pharma, BioNTech - Opportunities after the correction
After record highs for the DAX, Dow Jones, and the precious metal gold, the stock market has been burdened by a broad correction in recent days, which could spread further in the coming weeks. However, the setback offers many investors the opportunity to pick up their favorites once again at discounted levels. In addition to the highly volatile cannabis stocks, there are enormous opportunities in the biotech sector, where takeovers are on the rise.
Read
Commented by André Will-Laudien on May 30th, 2024 | 07:00 CEST
Already up 180% in 2024 - Who offers more? BioNTech, Bayer, Cardiol Therapeutics, or Evotec?
For investors in the biotech sector, 2024 has been a very rocky year. Everyone is waiting for the big breakthrough, which has yet to appear. In a sector where there is no longer a pandemic and cancer research is still stuck, selection has become very important. Complicating matters is the investor-unfriendly capital market interest rate, with hopes resting on support from central banks quarter by quarter. This makes it all the more important to identify and follow the most innovative business models. BioNTech does not currently have a blockbuster but still has a good EUR 17 billion in its coffers. Pharmaceutical giant Bayer has seen its share price drop to a fifth of its 2019 value, and Evotec also resembles a disaster. Cardiol Therapeutics has performed well so far - what is next for them?
Read
Commented by Fabian Lorenz on May 29th, 2024 | 07:00 CEST
Biotech stocks with a comeback! BioNTech, Evotec, Vidac Pharma
Avian flu has caused vaccine stocks such as BioNTech, Moderna and CureVac to soar in the past week; however, more is needed to ensure a sustainable comeback. BioNTech plans to achieve this with cancer drugs. In an interview with "Handelsblatt", BioNTech's CEO expressed his optimism about significantly reducing the mortality rate. The Mainz-based company plans to launch its first drugs on the market as early as 2026. Vidac Pharma is pursuing a revolutionary approach in the fight against cancer. The London-based biotech company has published promising study data and is being traded as a takeover candidate. And what about Evotec? The problem child of the current year has extended a partnership but continues to search for a trigger to drive its stock up.
Read
Commented by Juliane Zielonka on May 24th, 2024 | 07:00 CEST
NVIDIA, Vidac Pharma, Bayer - Opportunities for innovation and growth
The next industrial revolution has begun – companies and countries are working with firms like NVIDIA to transform traditional data centres worth billions of euros into accelerated computing hubs and build a new type of data centre: AI factories to produce artificial intelligence. The areas of application are vast, including data processing, generative AI, pharmaceutical research, weather simulations, robotics and many more. Vidac Pharma, for example, is an exciting candidate in the field of drug research. Their innovative approach in oncology can reverse the function of cancer cells. If successful, Bayer would have less to worry about. The Leverkusen-based company is fighting the wave of US lawsuits in connection with RoundUp®. The glyphosate-based herbicide is suspected of causing cancer. Bayer is now pursuing a new strategy in the face of the six-figure lawsuits. Where do investors find the best innovations and greatest growth opportunities?
Read
Commented by Juliane Zielonka on May 23rd, 2024 | 08:45 CEST
Defence Therapeutics, Super Micro Computer, Evotec: Fresh patents, revenue explosion, and cyberattacks - These companies overcome all hurdles
Medicine and research go hand in hand. The Canadian biotech company Defence Therapeutics is expanding its patent protection for its platform technology in order to further advance the development of drugs, vaccines, and active ingredients. Data collection and analysis require intelligent solutions such as those from Super Micro Computer. With an incredible 200% increase in revenue, the US company from Silicon Valley is surfing the digital wave of success. Will they continue to rise? Meanwhile, Evotec is grappling with the darker side of digitalization. Due to a cyberattack, the life sciences company is withdrawing from an otherwise lucrative segment. We provide the details.
Read
Commented by Stefan Feulner on May 22nd, 2024 | 07:00 CEST
BioNTech, Cardiol Therapeutics, Morphosys - On the verge of a breakout
Compared to the broader indices, DAX and Dow Jones, which have already reached new all-time highs, the Nasdaq Biotech Index is currently lagging. The sector index is still around 23% below its peak from August 2021. Nevertheless, the sector is on the move. In addition to takeovers, which have increased dramatically in 2024, many companies have important study results in the pipeline that could kick-start a rally.
Read
Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST
Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?
The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.
Read
Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST
Bayer, Defence Therapeutics, Novavax - Major events
The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.
Read
Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST
Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list
Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.
Read
Commented by Fabian Lorenz on May 8th, 2024 | 06:45 CEST
BUY RECOMMENDATIONS! Are Evotec, Super Micro Computer, and Royal Helium about to take off?
Evotec's share price has plummeted by around 50% this year. Consequently, the stock is among the year's losers. However, several buy recommendations are raising eyebrows. Is the turnaround imminent? The Royal Helium share is also ripe for a turnaround. The little-known noble gas is used in the defense industry, medical technology and for quantum computers, among other things. Royal Helium aims to transition from an explorer into a producer and has enlisted strong partners to achieve this. Will the share see a breakthrough after the ongoing capital increase? And what about Super Micro Computer? The AI high-flyer seems to have overcome its phase of weakness. Is it now heading for new all-time highs?
Read